Status: Not yet recruiting
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
The proposed study is an Open-Label, Single-Dose Study to Assess the Safety, and Pharmacodynamics (PD) signals of MRG-001 in Patients with Amyotrophic Lateral Sclerosis (ALS). MRG-001 will be administered subcutaneously 3 times per week for 2 weeks. This cycle will be repeated for 3 months. In total, patients are expected to receive 18 injections over the span of 3 months.
Participants needed: 10
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: MedRegen LLCUpdated: Aug 23, 2024
Eligibility criteria
Able to provide written informed consent (either from patient or patient's legal... [+9]
Participation in another interventional clinical trial (drug or device) within 3... [+15]